Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of ISIS 388626 in healthy volunteers
NL-OMON35464Phase 1Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jan 2009
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, double-blind trial of ISIS 388626 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Ionis Pharmaceuticals. Primary endpoints: Safety and tolerability, Pharmacokinetics and 2 more. Started Jan 2009; status: active, not recruiting.
02
Drugs
ISIS 388626
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON35464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35464.